- |||||||||| tolvaptan / Generic mfg., pioglitazone / Generic mfg.
Journal: Novel hits for autosomal dominated polycystic kidney disease (ADPKD) targeting derived by in silico screening on ZINC-15 natural product database. (Pubmed Central) - Jan 30, 2024 Farnesiferol B (16), compared to compound-10, showed binding affinity of -8.16, -6.4, -7.46, -6.92, and -6.11?kcal/mol against the above targets, respectively. Molecular dynamics, which was done on the compound-10 and 16 (Farnesiferol B) in complex with PPARG, GANAB, and AVPR2, showed more negative binding free-energy than Pioglitazone, Miglitol, and Tolvaptan as FDA-approved drugs for each target, respectively.Communicated by Ramaswamy H. Sarma.
- |||||||||| pioglitazone / Generic mfg.
Review, Journal: Peroxisome proliferator-activated receptor?/? agonist pioglitazone for rescuing relapsed or refractory neoplasias by unlocking phenotypic plasticity. (Pubmed Central) - Jan 26, 2024 Pioglitazone, integrated in differentially designed editing schedules, facilitated induction of tumor cell death as indicated by complete remission (CR) in r/r non-PML AML, continuous CR in r/r RCCC, mLCH, and in HL by addition of everolimus, or long-term disease control in melanoma by efficaciously controlling metastasis, post-therapy cancer repopulation and acquired cell-resistance and genetic/molecular-genetic tumor cell heterogeneity (M-CRAC)...Low-dose MCT facilitates targeted reprogramming of cancer hallmarks with transcriptional modulators, induction of tumor cell death, M-CRAC control and editing of non-oncogene addiction. Thus, pioglitazone, integrated in tumor tissue editing protocols, is an important biomodulatory drug for addressing urgent therapeutic problems, such as M-CRAC in relapsed or refractory tumor disease.
- |||||||||| pioglitazone / Generic mfg., acarbose / Generic mfg.
Preclinical, Journal: 3,5-Disubstituted-thiazolidine-2,4-dione hybrids as antidiabetic agents: Design, synthesis, in-vitro and In vivo evaluation. (Pubmed Central) - Jan 22, 2024 The compounds 7i, 7k, and 7p were evaluated in vivo antidiabetic activity in an STZ-induced diabetic model in Wistar rats. The compound 7p emerged as the best compound in the in vivo studies; however, the activity was lesser than that of the standard drug pioglitazone.
- |||||||||| pioglitazone / Generic mfg.
Journal, IO biomarker: Intervention effect of Cigu Xiaozhi prescription on ceramide lipoapoptosis in non-alcoholic fatty liver disease. (Pubmed Central) - Jan 16, 2024 In conclusion, teriparatide leads to a significantly greater rise in lumbar spine BMD in postmenopausal women with T2D at a high-risk of fragility fractures, however, a longer duration of follow-up is required to yield meaningful incident fracture data. The CGXZ prescription, formulated with the method of detoxification and phlegm, can inhibit lipoapoptosis in the NAFLD cell model by down-regulating the levels of ceramide C2 and FFA, which may be achieved by regulating ceramide/iNOS/NF-?B signaling pathway.
- |||||||||| metformin / Generic mfg., sildenafil / Generic mfg., pioglitazone / Generic mfg.
Review, Journal: SIRT1/SREBPs-mediated regulation of lipid metabolism. (Pubmed Central) - Jan 15, 2024 Hence, the objective of this analysis was to investigate and elucidate the correlation between SIRT1 and SREBPs, as well as assess the contribution of SIRT1/SREBPs in mitigating lipid metabolism dysfunction. The objective of this research was to investigate whether SIRT1 and SREBPs could be utilized as viable targets for therapeutic intervention in managing complications associated with diabetes.
- |||||||||| pioglitazone / Generic mfg.
Review, Journal, Heterogeneity, Tumor cell, Metastases: Addressing Genetic Tumor Heterogeneity, Post-Therapy Metastatic Spread, Cancer Repopulation, and Development of Acquired Tumor Cell Resistance. (Pubmed Central) - Jan 11, 2024 In contrast to conventional chemotherapy or state-of-the-art precision medicine, tissue editing employs a multi-pronged approach targeting important drivers of M-CRAC across various tumor entities, thereby, simultaneously engaging tumor cell differentiation, immunomodulation, and inflammation control. In this review, we highlight the M-CRAC concept as a major factor in resistance to conventional cancer therapies and discusses tissue editing as a potential treatment.
- |||||||||| pioglitazone / Generic mfg.
Review, Journal: A Comprehensive Review on Non-Alcoholic Fatty Liver Disease. (Pubmed Central) - Jan 8, 2024 A healthy diet, physical exercise, and a decrease in weight are advised by current international guidelines for the treatment of NAFLD, along with a limited number of medicinal therapies, including vitamin E and pioglitazone...This article assesses MASLD's pathophysiology, diagnosis, treatment, and epidemiology. This study also reviews a few natural substances that have been shown to have therapeutic advantages for NAFLD.
- |||||||||| Duvie (lobeglitazone) / Chong Kun Dang
Review, Journal: Lobeglitazone and Its Therapeutic Benefits: A Review. (Pubmed Central) - Jan 8, 2024 Side effects of lobeglitazone included peripheral edema, weight gain, and bone mineral density, which did not require hospitalization for these effects. This article
- |||||||||| Comparative efficacy of pharmacologic therapies in MASH: Systematic review and meta-analysis (New Hall) - Jan 6, 2024 - Abstract #APASL2024APASL_707;
For MRI-PDFF response, Aldafermin (SUCRA = 92.61), Efruxifermin (SUCRA = 81.00) and Resmetirom (SUCRA = 55.54) had the highest probability of being ranked the most effective intervention for achieving MRI-PDFF response at week 12. These data provide relative rank-order efficacy of various MASH therapies in terms of improvements in MRI-PDFF.
- |||||||||| pioglitazone / Generic mfg.
Review, Journal: Non-alcoholic fatty liver disease: aspects of management of a comorbid patient. A review (Pubmed Central) - Jan 6, 2024 In the treatment of comorbid patients, some groups of hypoglycemic drugs are used, including ar-GLP-1, i-NGL-2, pioglitazone, lipid-lowering drugs, drugs for the treatment of obesity...According to a number of studies, EFL helps to reduce the severity of steatosis, improving both objective and subjective manifestations of hepatic dysfunction. In this connection, the guidelines of various countries include EFL group drugs in the protocol of treatment of patients with NAFLD both in monotherapy and in combination with other drugs.
- |||||||||| pioglitazone / Generic mfg.
Journal: Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Retinopathy in Patients With Type 2 Diabetes. (Pubmed Central) - Dec 20, 2023 This cohort study found that SGLT2i was associated with a lower risk of sight-threatening retinopathy compared with DPP-4i, pioglitazone, and sulfonylureas. This finding suggests that SGLT2i may play a role not only in reduced risk of diabetic nephropathy but also in the slow progression of diabetic retinopathy in patients with T2D.
- |||||||||| pioglitazone / Generic mfg., rosiglitazone / Generic mfg., fenofibrate / Generic mfg.
Impact of peroxisome proliferator-activated receptor agonists on myosteatosis in the context of metabolic dysfunction-associated steatotic liver disease (Teun - Hilton Antwerp Old Town) - Dec 19, 2023 - Abstract #BWG2024BWG_28; agonist pioglitazone alone...In another preclinical study in ZDF rats, the combination of fenofibrate (PPAR?) and rosiglitazone (PPAR?) did not significantly reduce gastrocnemius muscle triglyceride content (assessed by triglyceride extraction), but did with fenofibrate alone...Further clinical research is required to fully evaluate the efficacy of these treatments on both MASH components and myosteatosis. We believe that myosteatosis should be adequately evaluated in future studies on MASLD/MASH.
- |||||||||| Trial completion date: HbA1c Variability in Type II Diabetes (clinicaltrials.gov) - Dec 15, 2023
P=N/A, N=150, Active, not recruiting, The results showed that the devised probe may be employed as an easy, sensitive, and precise approach for detecting Pio in real samples. Trial completion date: Oct 2023 --> Oct 2024
- |||||||||| pioglitazone / Generic mfg.
Review, Journal: NAFLD and type 2 diabetes: A practical guide for the joint management. (Pubmed Central) - Nov 27, 2023 Therefore, a close collaboration between primary care physician, endocrinologists and hepatologists is essential to optimize the management of patients with NAFLD and T2D. Here, we summarize relevant aspects about NAFLD and T2D that all clinician managing these patients should know as well as current therapeutic options for the treatment of T2D associated with NAFLD.
- |||||||||| pioglitazone / Generic mfg.
Journal: Double Attack to Oxidative Stress in Neurodegenerative Disorders: MAO-B and Nrf2 as Elected Targets. (Pubmed Central) - Nov 18, 2023 Furthermore, the same compound proved to activate Nrf2 pathway by potently increasing Nrf2 nuclear translocation and strongly reducing ROS content, both in physiological and stressed conditions. Although further biological investigations are required to fully clarify its neuroprotective properties, we were able to endow the pioglitazone scaffold with potent antioxidant properties, representing the starting point for potential future pioglitazone-based therapeutics for neurodegenerative disorders.
- |||||||||| pioglitazone / Generic mfg.
Review, Journal, Adverse events: Association of Pioglitazone With Major Adverse Cardiovascular Events, All-Cause Mortality, and Heart Failure Hospitalizations: A Systematic Review. (Pubmed Central) - Nov 13, 2023 Despite the fact that initial research acknowledged fluid retention as a safety issue in pioglitazone use, clinical trial data have not presented conclusive proof of a positive or negative impact on cardiac function. This comprehensive literature review aims to evaluate the effect of pioglitazone on all-cause mortality, hospitalizations for heart failure, and major adverse cardiovascular outcomes, including the individual outcomes of non-fatal stroke, non-fatal myocardial infarction, and cardiovascular mortality.
|